


Supplemental Fig. 1 Study Design for ATMOS-1 and ATMOS-2 Trials



For subjects not enrolling in ARIDO, telephone follow-up occurred in Week 5 to record adverse events and concomitant medications.

<sup>a</sup>Gravimetrically-measured. ET, end of treatment for ATMOS-1 and ATMOS-2; GT, glycopyrronium tosylate; Wk, Week

Supplemental Fig. 2 ASDD Items 2, 3, and 4 at Baseline: Proportion of Patients at Different Threshold Score Cutoffs (Pooled Population)

